Clinical Trial Update: Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating metabolic cofactor supplementation in obese patients with non-alcoholic fatty liver disease has completed. The record notes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Metabolic Cofactor Supplementation (metabolic cofactor supplementation)

Snippet

Sponsor: ScandiBio Therapeutics AB | Conditions: Non-alcoholic Fatty Liver Disease (NAFLD) | Phase 2 | Status: COMPLETED